CSIMarket Company Name, Ticker, Industry, else..
 
Galectin Therapeutics Inc   (NASDAQ: GALT)
 

Galectin Therapeutics Inc's Suppliers Performance

GALT's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
GALT Costs vs Sales of Suppliers Growth

• More on GALT Suppliers






Galectin Therapeutics Inc's Comment on Supply Chain


The company manufactures its products on a purchase-order basis from two primary pharmaceutical suppliers that comply with FDA requirements. Belapectin is produced as a sterile liquid formulation. The company has experienced and may continue to experience delays due to global supply chain issues affecting certain components necessary for manufacturing belapectin. As the products are in the development stage, the company has not established a sales and marketing staff and may rely on third parties, including licensees, collaborators, joint venture partners, or independent distributors, for commercialization. Reliance on third-party manufacturers, analytical testing laboratories, and marketers involves risks related to reduced control.

Galectin Therapeutics Inc's Comment on Supply Chain


The company manufactures its products on a purchase-order basis from two primary pharmaceutical suppliers that comply with FDA requirements. Belapectin is produced as a sterile liquid formulation. The company has experienced and may continue to experience delays due to global supply chain issues affecting certain components necessary for manufacturing belapectin. As the products are in the development stage, the company has not established a sales and marketing staff and may rely on third parties, including licensees, collaborators, joint venture partners, or independent distributors, for commercialization. Reliance on third-party manufacturers, analytical testing laboratories, and marketers involves risks related to reduced control.







GALT's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Galectin Therapeutics Inc 260.87 0.00 -27.84 9
SUBTOTAL 0.00 0.00 0.00 -


Sources: Galectin Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Galectin Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.